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Telemedicine: An Evolving Field in
Hepatology
Cindy Piao,1 Norah A. Terrault,2,3 and Souvik Sarkar1,4

Healthcare delivery has been dramatically changing in recent times with advances in technology. One area of expansion has been the use of telemedicine due to progression in communication technologies. Telemedicine offers the
opportunity to overcome barriers of access, improve patient satisfaction, improve healthcare outcomes and streamline
communication between patients and providers. The primary modalities of telemedicine can be grouped into categories of ‘remote monitoring,’ ‘store and forward’ and ‘interactive telemedicine.’ These modalities of telemedicine have
been practiced and explored within the scope of hepatology such as in liver transplantation, hepatocellular carcinoma
and management of chronic hepatitis C (CHC). There are numerous telemedicine-based CHC management studies
and programs that have developed in New Mexico, the Department of Veterans Affairs, as well as globally in
Australia and Canada. In Northern California, the University of New Mexico telemedicine-based model of ‘ECHO’
has been extended to develop community-based champions to screen-link-treat CHC patients with the goal to eliminate hepatitis C. Despite the advantages to telemedicine, there are still many barriers to seamless integration due to
reimbursement and up-front cost. Nevertheless, it remains an essential part in providing world-class care to liver
patients across geographic and economic barriers. (Hepatology Communications 2019;3:716-721).

I

n the world of smartphones, applications, social
media, and electronic health record portals, delivery and communication in health care have drastically changed. Telemedicine is a rapidly expanding
area of health care delivery. The term itself denotes
“healing at a distance” and was coined in the 1970s.
According to the World Health Organization, telemedicine needs to have four elements: provide clinical support, overcome geographic barriers to connect
individuals that are not in the same physical location,
involve various communication technologies, and
improve health outcome.(1) The greatest driving force
for the advancement of telemedicine has been the
rapid advancement and availability of mobile communication technologies along with expansion of wireless

broadband technology. Telemedicine deviates from the
traditional patient–physician office visit. Importantly,
it can overcome barriers to access as many patients are
unable to travel to see a specialist or provider due to
distance, financial reasons, or simply inconvenience.
With specialized care typically limited to larger
urban areas, there is a significant need for advancements of telemedicine to connect patients in remote or
rural areas with health care providers in urban areas.
Ultimately, if telemedicine can enhance patient access
to providers and/or provide improved continuity of
care, there is an opportunity to improve health care
outcomes. In this article, we delve into how telemedicine can impact hepatology practice and help in the
understanding of challenges and future directions.

Abbreviations: CHC, chronic hepatitis C; DAA, direct-acting antiviral; ECHO, Extension for Community Healthcare Outcomes; HCV,
hepatitis C virus; PCP, primary care physician; SVR, sustained virologic response; UC, University of California; VA, Veterans Affairs.
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FIG. 1. Different modalities of telemedicine.

A Primer of Telemedicine
Terminology

Telemedicine and telehealth are used interchangeably. The primary modalities of telehealth or telemedicine can be grouped into three categories: “remote
monitoring,” “store and forward,” and “interactive
telemedicine” (Fig. 1). These different modalities contribute to improving patient health in different but
overlapping ways.

REMOTE MONITORING
Telemonitoring generally refers to tracking various patient parameters, usually through mobile
devices or reporting by telephone. An example is
home monitoring of daily weights, blood pressure,
and pulse in patients with congestive heart failure;
the data are then transmitted to a monitoring database. Tele-interpretation often uses asynchronous
telemedicine that requires remote monitoring and
interpretation of medical data by distant medical
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professionals; this is commonly used in radiology or
pathology and can be seen in practice with interpretation of electrocardiograms by remote cardiologists.

INTERACTIVE TELEMEDICINE
Interactive telemedicine is synchronous real-time
patient management. It includes teleconsultation in
collaboration with specialists who are available at tertiary centers but unable to be physically present at
community and rural hospitals. Commonly, community hospitals have access to pulmonary critical care
doctors at a tertiary care center through teleconsultation; these doctors can guide on-site hospitalists
in critical care medical decisions. Televisits are conventional patient–provider office visits that use video
and audio conferencing due to distance; televisits are
a form of interactive telemedicine or store and forward. With advents in digital diagnostic tools, such as
digital stethoscopes and otoscopes, televisits can be as
comprehensive as an in-person clinic visit.

STORE AND FORWARD
Store and forward is also known as asynchronous
telemedicine and refers to storing a patient’s information, which is then later analyzed by a medical professional. This contrasts with real-time communication

seen in interactive telemedicine where a clinician
interacts with a patient in real time by video and
audio conferencing. Tele-education generally uses the
concept of store and forward and has been practiced
for many years through online teaching didactics and
interactive videos for patients as well as providers.

Telemedicine and Hepatitis C

Early management of chronic hepatitis C (CHC)
was challenging and generally restricted to academic
medical centers or specialty care. The advent of telemedicine and innovative methodology from New
Mexico helped transform the treatment of CHC. The
telemedicine-based CHC management studies and
programs are summarized in Table 1. One of the most
well-known studies in hepatology is the Extension for
Community Healthcare Outcomes (ECHO) project created at the University of New Mexico Health
Sciences Center to delivery CHC treatment in rural
and underserved populations in New Mexico.(2) In this
single-site, prospective, cohort study, primary care physicians/providers (PCPs) undertook weekly videoconferences with specialists as well as short didactic sessions
along with discussions of patient treatment plans. The
study comprised 407 subjects in the ECHO study arm

TABLE 1. SUMMARY OF VARIOUS TELEMEDICINE-BASED CHC PROGRAMS
Type of TM
Subjects

Article
Arora et al.(2)

Rural

Number of Subjects
TM n = 261
Clinic n = 146

Nazareth et al.(11)

Rural

TM n = 50
Clinic n = 559

Rossaro et al.(12)

Rural

Beste et al.(3)

Rural veterans

TM n = 40

Study Design
Prospective cohort
study

Clinic 58%

Prospective cohort
study

Clinic 59%

Retrospective cohort
study

Clinic n = 40
TM n = 6,431
Clinic n = 32,322
Cooper et al.(4)

Rural

TM n = 157
Clinic n = 1,130

Sterling et al.(13)

Incarcerated

TM n = 84
Clinic n = 240

SVR
TM 58%
TM 71%
TM 55%

Treatment Type

Country

Interferon and
ribavirin

USA

Interferon and
ribavirin

Australia

Interferon and
ribavirin

USA

Clinic 43%
Prospective cohort
study

Clinic 54%

TM 58%

Retrospective cohort
study

Clinic 95%

Prospective cohort
study

Clinic 94%

TM 95%
TM 95%

Interferon +/– ribavirin, USA
DAA
DAA

Canada

DAA

USA

Talal et al.(14)

OST

TM n = 62

Prospective cohort
study

TM 93%

DAA

USA

Papaluca et al.(15)

Incarcerated

TM n = 313

Prospective cohort
study

TM 96%

DAA

Australia

Abbreviations: OST, opioid substitution therapy; TM, telemedicine.
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that received CHC interferon treatment administered
by PCPs and 146 controlled subjects that received the
same CHC treatment at the University of New Mexico
hepatitis C virus (HCV) clinic. Results showed that
sustained virologic responses (SVRs) or viral eradication were similar in the ECHO study arm (58.2%) and
controlled arm (57.5%; no significant difference). Over
the years, ECHO has transformed many practices for
CHC treatment nationally and internationally and has
also percolated through multiple different specialties.
The Department of Veterans Affairs (VA) adopted
a similar model for treatment of CHC called the
VA Extension for Community Health Outcomes
(VA-ECHO) to reach the rural VA patient population. VA-ECHO was implemented in 152 PCP sites
nationwide. PCPs received videoconferencing with
specialists every 1-2 weeks with collaborative discussions of patient treatment plans. In the study, 4,173
subjects were exposed to VA-ECHO and 32,322 subjects were unexposed. Subjects were treated with direct
antiviral drugs for treatment of CHC with no difference in rate of SVR in the two populations. However,
the study noted that the rate of PCP-initiated antiviral treatment was much higher in subjects exposed
to VA-ECHO compared to patients who were unexposed (21.4% versus 2.5%, respectively). This study
suggests that further implementation of VA-ECHO
will improve rates of initiation of CHC treatment
in the VA population.(3) Similarly, comparison of
telehealth-based care of the rural patient population
versus the urban population having access to direct
clinical care had similar rates of SVR (94.7% versus
94.8%, respectively) when using new-generation antivirals for CHC (direct-acting antivirals [DAAs]).(4)
The University of California (UC) San Francisco
uses the ECHO model to expand CHC treatment
capacity in northern California. More than 50 providers in over 20 counties are actively engaged in HCV
management. Although this made significant roadway
into the management of hepatitis C, an expanded version of ECHO was launched in 2018, called ECHOplus, in collaboration with UC Davis and their
telemedicine program. While ECHO takes a oneto-many (specialist hub with PCP spokes) approach,
UC Davis telemedicine is one-to-one telementoring
with the HCV specialist–provider–patient. A unique
aspect of the program is the ability to tailor the training based on the provider or practice needs. To further provide a comprehensive service to the providers,
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FIG. 2. Model of ECHO-plus at UC San Francisco and UC
Davis.

ECHO-plus includes pharmacist-driven training of
the DAAs and their approval, a clinical management
support tool, and access to a “warm line” (Fig. 2). The
joint program has already enrolled PCPs from 30 centers across rural northern California in the past year.(5)
Telemedicine is a vital tool for the goal of elimination of hepatitis C. Continual efforts in innovations of
telemedicine to cater to the local needs will be essential for the treatment of hepatitis C.

Telemedicine for
Hepatocellular Carcinoma

In patients with hepatocellular carcinoma who are
cared for at institutions without tumor board forums,
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virtual tumor boards can expedite the process of multidisciplinary evaluation. At the VA, patients enrolled
in virtual tumor boards received high rates of comprehensive multidisciplinary evaluation within a shorter
amount of time.(6)

Telemedicine Expanding Into
Other Areas of Hepatology

Telemedicine has also gained traction in other
areas of hepatology (Table 2). In populations before
and after liver transplant, telehealth-based approaches
have been shown to improve patient satisfaction.(7)
The innovative telemedicine-based approach also
streamlined communication between transplant surgeons for allocation of grafts in split liver transplantation.(8) In patients with alcoholic cirrhosis, frequent
teleconsultations appeared to prevent relapse, reduce
hospitalization, and increase quality of life. A recent
pilot study showed an automated telephone monitoring system could be used to predict future hospitalizations in patients with decompensated cirrhosis.(9)

Challenges With
Telemedicine Implementation

Numerous challenges remain in the integration of
telemedicine into clinical practice. One of the significant barriers is restriction on reimbursements.
At this time, there are stringent rules to be eligible

for Medicare reimbursement for telemedicine services.(10) Patients must be located outside a metropolitan statistical area. Patients also need to be
located within approved “originating sites,” such as
office, clinic, or nursing home, with interactive audio
and video telecommunication systems for real-time
communication in order to quality for reimbursements. Clinicians often need to be licensed with
malpractice insurance at the originating sites to
receive reimbursement.(10) Reimbursement process
and rates have also been confusing across insurers.
Private payer reimbursements for telemedicine services are variable. Currently, there are different state
policies regarding reimbursement for telehealth
services. The lack of guidelines and uniformity of
reimbursement create varying degrees of incentive
to invest in telemedicine.
Although telemedicine holds significant potential, telemedicine is not ubiquitous. It requires large
upfront costs to the institution to implement, along
with additional support for legal liabilities, security
of data, and training. Thus, it will require significant
cultural change, including modifications to teaching
and management techniques. Telemedicine has been
studied in many specialties and clinical settings; yet,
few studies have analyzed its cost effectiveness.

Concluding Remarks

Telehealth offers unique opportunities to patients
and providers. As the field of medicine progresses,
disparities in health care and access remain through all

TABLE 2. USE OF TELEMEDICINE IN DIFFERENT AREAS OF HEPATOLOGY
Condition

Articles
Arora et al.(2)
Nazareth et al.(11)
Rossaro et al.(12)
Beste et al.(3)
Cooper et al.(4)
Sterling et al.(13)
Talal et al.(14)
Papaluca et al.(15)

Conclusion

HCV

-

Hepatocellular carcinoma

- Salami et al.(6)

- Virtual tumor boards expedite process of multidisciplinary evaluation in patients with
hepatocellular carcinoma.

Cirrhosis

- Thomson et al.(9)

- Teleconsultations can prevent relapse and reduce hospitalization.

Liver transplantation

- Reddy et al.(8)
- Ertel et al.(7)

- Telemedicine can help streamline communication between transplant surgeons.
- Improved patient satisfaction before and after transplant with help through
telemedicine.
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- There is no difference in SVR in patients who underwent telemedicine consultation or
standard clinic visits.
- Various studies show that rates of initiation of therapy for HCV are higher in the
telemedicine group compared to hepatologist-treated patients with HCV.
- Telemedicine is an effective tool for treatment of HCV in patients who are incarcerated
or located in remote regions.
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specialties. Evolving technological advances can help
address some of these challenges by integrating care
and increasing access while maintaining or reducing
costs. Telemedicine is certainly reaching prime time,
thus providing world-class care to all our liver patients
across geographic and economic barriers. Telehealth
should be the logical extension of clinical care for all
academic and tertiary medical centers.
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8)
9)
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